These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 2102337)

  • 1. Benign pathology of the ovary.
    O'Connor DM
    Curr Opin Obstet Gynecol; 1990 Jun; 2(3):422-9. PubMed ID: 2102337
    [No Abstract]   [Full Text] [Related]  

  • 2. Significant increases in serum CA125 and CA19-9 following torsion from an adenofibroma of the ovary: a case report.
    Fujiwara K; Moriya T; Mikami Y; Hiratsuka J; Sawada S; Imajo Y; Kohno I
    Jpn J Clin Oncol; 1994 Apr; 24(2):116-9. PubMed ID: 8158859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Familial cancer of the ovary. A family with 6 index cases].
    de Meeus JB; Bennouna C; Maréchaud M; Plocoste V; Magnin G
    J Gynecol Obstet Biol Reprod (Paris); 1993; 22(7):749-56. PubMed ID: 8308201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pelvic tumor, elevated CA 125 level and tuberculosis].
    Belletti GA; Millán AE; López A; Yorio MA; Jakob E; Bouchet D; Irico G
    Medicina (B Aires); 2005; 65(2):181-2. PubMed ID: 16075819
    [No Abstract]   [Full Text] [Related]  

  • 5. Ovarian cancer of epithelial origin--an update.
    Menczer J
    Isr J Med Sci; 1993 Aug; 29(8):477-83. PubMed ID: 8407278
    [No Abstract]   [Full Text] [Related]  

  • 6. Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases.
    Riisbro R; Stephens RW; Brünner N; Christensen IJ; Nielsen HJ; Heilmann L; von Tempelhoff GF
    Gynecol Oncol; 2001 Sep; 82(3):523-31. PubMed ID: 11520150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical evaluation of tumor-associated mucin-type glycoprotein CA 54/61 in ovarian cancers: comparison with CA 125.
    Suzuki M; Sekiguchi I; Tamada T
    Obstet Gynecol; 1990 Sep; 76(3 Pt 1):422-7. PubMed ID: 2381620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Considerations on some histological aspects of the ovary in the post-menopausel period].
    Bonfirraro G; Forleo R; Buzzoni P
    Quad Clin Ostet Ginecol; 1966 Dec; 21(12):1049-60. PubMed ID: 5994951
    [No Abstract]   [Full Text] [Related]  

  • 9. [Studies on clinical usefulness of new tumor markers of ovarian cancer, CA54/61 and CA602--III. Measurement of serum samples from patients with various benign or malignant diseases].
    Nozawa S; Udagawa Y; Sasaki H; Ito K; Akiya K; Terashima Y; Takamizawa H; Ohkura H; Fujimoto S; Hashimoto M
    Gan To Kagaku Ryoho; 1994 May; 21(6):823-32. PubMed ID: 8185340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preoperative serum tetranectin, CA125 and menopausal status used as single markers in screening and in a risk assessment index (RAI) in discriminating between benign and malignant ovarian tumors.
    Begum FD; Høgdall E; Kjaer SK; Blaakaer J; Christensen IJ; Christensen L; Høgdall C
    Gynecol Oncol; 2009 May; 113(2):221-7. PubMed ID: 19261323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor-associated trypsin inhibitor (TATI) and cancer antigen 125 (CA125) in patients with epithelial ovarian cancer.
    Peters-Engl C; Medl M; Ogris E; Leodolter S
    Anticancer Res; 1995; 15(6B):2727-30. PubMed ID: 8669854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retrospective and prospective study of ovarian tumours and tumour-like lesions.
    Gupta N; Bisht D; Agarwal AK; Sharma VK
    Indian J Pathol Microbiol; 2007 Jul; 50(3):525-7. PubMed ID: 17883123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoplastic and non-neoplastic ovarian disease in Zimbabwean women.
    Stanczuk G
    Cent Afr J Med; 1995 Sep; 41(9):274-8. PubMed ID: 8591636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Detection of CA 125 in the serum and tissue of patients with ovarian neoplasms].
    Kristen P; Beier HJ; Kaesemann H; Caffier H
    Gynakol Rundsch; 1989; 29 Suppl 2():358-60. PubMed ID: 2693257
    [No Abstract]   [Full Text] [Related]  

  • 15. Immunohistochemical localization of tyrosine receptor kinases A and B in endometriosis-associated ovarian cancer.
    Foster WG; Elias R; Faghih M; Dominguez MA; Elit L; Boutross-Tadross O
    Histopathology; 2009 Jun; 54(7):907-12. PubMed ID: 19635108
    [No Abstract]   [Full Text] [Related]  

  • 16. The relevance of angiogenesis in benign and malignant epithelial tumors of the ovary: a quantitative histologic study.
    Brustmann H; Riss P; Naudé S
    Gynecol Oncol; 1997 Oct; 67(1):20-6. PubMed ID: 9345351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Ovarian actinomycosis].
    Tolpinskiĭ AP; Bakhlaev IE; Bubnov VA
    Arkh Patol; 1993; 55(3):78. PubMed ID: 7944979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical analysis of 25 cases of malignant transformation of endometriosis of the ovary].
    Qian J; Shi Y; Chen X
    Zhonghua Fu Chan Ke Za Zhi; 2000 Nov; 35(11):667-9. PubMed ID: 11218895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The CA-125 tumor marker in epithelial ovarian cancers of stage I].
    Nagele F; Vavra N; Kurz C; Sevelda P
    Wien Klin Wochenschr; 1993; 105(20):585-8. PubMed ID: 8259686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preoperative evaluation of D-dimer and CA 125 levels in differentiating benign from malignant ovarian masses.
    Gadducci A; Baicchi U; Marrai R; Ferdeghini M; Bianchi R; Facchini V
    Gynecol Oncol; 1996 Feb; 60(2):197-202. PubMed ID: 8631538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.